Association between Selective Serotonin Reuptake Inhibitor Therapy and Suicidality: Analysis of U.S. Food and Drug Administration Adverse Event Reporting System Data

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are prescribed for the treatment of depression worldwide. SSRIs are suspected to increase the risk of suicidal ideation and behavior (suicidality) in children, adolescents, and young adults. We examined the association between SSRI therapy and suicidality by applying a logistic regression model to age-stratified data from the Food and Drug Administration (FDA) Adverse Event Reporting System database. We attempted to mitigate the effect of patient-related factors by data subsetting. We selected case reports for SSRIs as referred to in the World Health Organization Anatomical Therapeutic Chemical classification code N06AB. The association between SSRIs and "suicidal events" or "self-harm events" was calculated as a reporting odds ratio (ROR) and adjusted for covariates by logistic regression. For subjects <18 years old (y.o.) the adjusted RORs (95% confidence interval) of SSRI therapy with suicidal events were 9.58 (8.97-10.23) in the whole data analysis and 4.64 (4.15-5.19) in the subset analysis; those with self-harm events were 31.40 (27.71-35.58) and 16.31 (13.12-20.29), respectively. Although the adjusted RORs were lower in the subset analyses than in the whole data analyses, both analyses indicated associations between SSRI treatment and suicidal and self-harm events. In both analyses these associations were stronger in the <18 y.o. group than other age groups. Children and adolescents should be closely monitored for the occurrence of suicidality when they are prescribed SSRIs. In addition, we found that data subsetting might mitigate the effect of an intrinsic risk among patients taking the suspected drug.Key words selective serotonin reuptake inhibitor (SSRI); suicidality; adverse event; reporting odds ratio (ROR) Selective serotonin reuptake inhibitors (SSRIs) are prescribed for the treatment of depression worldwide.

Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database

“…22,23 The data subsetting strategy may help mitigate indication bias on signal detection by limiting the analysis to a population of patients that are thought to share common risk factors and diseases. [24][25][26][27] We defined a patient subset with anticancer therapies from the whole JADER data and evaluated the intra-class RORs of this subset. We extracted the purpose of administration from the cases that were administered ICIs as listed in the "drug" table of the JADER database.…”

Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004–2015

“…Pharmacovigilance indexes, such as the ROR, have been developed to detect drug‐associated adverse events in the SRS, but these cannot be applied to evaluate the comparative strength of causalities (Bates & Evans, ). The ROR is a clear and easily applicable technique that allows for the control of covariates through logistic regression analysis (Abe et al., ; Suzuki et al., ; Ueda et al., ; Umetsu et al., ). An additional advantage of using the ROR is that non‐selective underreporting of a drug or adverse events has no influence on the value of the ROR compared with the population of patients experiencing an adverse event (Van der Heijden, van Puijenbroek, van Buuren, & van der Hofstede, ).…”

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system

“…The FAERS database is subject to various biases such as under-reporting, over-reporting, exclusion of healthy individuals, and confounding by comorbidities [ 18 ]. The data subsetting strategy may help to mitigate the effect of confounding factors and bias on signal detection by limiting the analysis to a population of patients that are thought to share common risk factors and diseases [ 15 , 16 , 34 – 36 ].…”